289 related articles for article (PubMed ID: 21339222)
1. Targeted therapies in systemic lupus erythematosus: successes, failures and future.
Hahn BH
Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i64-i66. PubMed ID: 21339222
[TBL] [Abstract][Full Text] [Related]
2. Belimumab: review of use in systemic lupus erythematosus.
Boyce EG; Fusco BE
Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
[TBL] [Abstract][Full Text] [Related]
3. [Allergo-immunology. Clinical immunology].
Chizzolini C
Rev Med Suisse; 2012 Jan; 8(323):11-3. PubMed ID: 22303732
[TBL] [Abstract][Full Text] [Related]
4. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
Dooley MA; Houssiau F; Aranow C; D'Cruz DP; Askanase A; Roth DA; Zhong ZJ; Cooper S; Freimuth WW; Ginzler EM;
Lupus; 2013 Jan; 22(1):63-72. PubMed ID: 23263865
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil in the treatment of systemic lupus erythematosus.
Dall'Era M
Curr Opin Rheumatol; 2011 Sep; 23(5):454-8. PubMed ID: 21720247
[TBL] [Abstract][Full Text] [Related]
6. Belimumab: targeted therapy for lupus.
Chugh PK; Kalra BS
Int J Rheum Dis; 2013 Feb; 16(1):4-13. PubMed ID: 23441766
[TBL] [Abstract][Full Text] [Related]
7. Open label randomized controlled trial assessing the efficacy of mycophenolate sodium against other conventional immunosuppressive agents in active systemic lupus erythematosus patients without renal involvement.
Yahya F; Jasmin R; Ng CT; Cheah TE; Sockalingam S
Int J Rheum Dis; 2013 Dec; 16(6):724-30. PubMed ID: 24119227
[TBL] [Abstract][Full Text] [Related]
8. Belimumab for the treatment of systemic lupus erythematosus.
Jordan N; D'Cruz DP
Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
[TBL] [Abstract][Full Text] [Related]
9. [What's new in internal medicine: emerging treatments for systemic lupus erythematosus].
Hachulla É
Ann Dermatol Venereol; 2011 Dec; 138 Suppl 4():S241-4. PubMed ID: 22202645
[TBL] [Abstract][Full Text] [Related]
10. Biologic therapies in systemic lupus erythematosus.
Bernal CB; Zamora LD; Navarra SV
Int J Rheum Dis; 2015 Feb; 18(2):146-53. PubMed ID: 25884458
[TBL] [Abstract][Full Text] [Related]
11. Systemic lupus erythematosus: an update on current pharmacotherapy and future directions.
Touma Z; Urowitz MB; Gladman DD
Expert Opin Biol Ther; 2013 May; 13(5):723-37. PubMed ID: 23339281
[TBL] [Abstract][Full Text] [Related]
12. Current role of rituximab in systemic lupus erythematosus.
Mok CC
Int J Rheum Dis; 2015 Feb; 18(2):154-63. PubMed ID: 25522652
[TBL] [Abstract][Full Text] [Related]
13. Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.
Davis LS; Reimold AM
Rheumatology (Oxford); 2017 Apr; 56(suppl_1):i100-i113. PubMed ID: 28375452
[TBL] [Abstract][Full Text] [Related]
14. Novel Treatments in Lupus.
Kyttaris VC
Curr Rheumatol Rep; 2017 Mar; 19(3):10. PubMed ID: 28265845
[TBL] [Abstract][Full Text] [Related]
15. Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus.
Wiglesworth AK; Ennis KM; Kockler DR
Ann Pharmacother; 2010 Dec; 44(12):1955-61. PubMed ID: 21081710
[TBL] [Abstract][Full Text] [Related]
16. Belimumab: a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.
Dennis GJ
Clin Pharmacol Ther; 2012 Jan; 91(1):143-9. PubMed ID: 22130121
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index.
Kalunian KC; Urowitz MB; Isenberg D; Merrill JT; Petri M; Furie RA; Morgan-Cox MA; Taha R; Watts S; Silk M; Linnik MD
Rheumatology (Oxford); 2018 Jan; 57(1):125-133. PubMed ID: 29045736
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis.
Kizawa T; Nozawa T; Kikuchi M; Nagahama K; Okudela K; Miyamae T; Imagawa T; Nakamura T; Mori M; Yokota S; Tsutsumi H
Mod Rheumatol; 2015 Mar; 25(2):210-4. PubMed ID: 25159157
[TBL] [Abstract][Full Text] [Related]
19. Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies.
Dall'era M; Chakravarty EF
Curr Rheumatol Rep; 2011 Aug; 13(4):308-16. PubMed ID: 21584692
[TBL] [Abstract][Full Text] [Related]
20. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
Merrill JT; Wallace DJ; Petri M; Kirou KA; Yao Y; White WI; Robbie G; Levin R; Berney SM; Chindalore V; Olsen N; Richman L; Le C; Jallal B; White B;
Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
